Benjamin P. Saylor

In national emergency department data from 2005 to 2024, fractures were the most common pediatric e-bike injury, and e-bikes had the second-highest admission rate.

An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.

A joinpoint analysis of 1991 to 2021 YRBSS data found suicidal ideation among US high school students declined through 2009, then increased through 2021.

A clinician-reported misinformation tracker at Children's Hospital of Philadelphia found vaccines accounted for 53.8% of 234 entries and informed education on 28 topics.

In a cross-sectional study of 48,118 pediatric primary care encounters, e-cigarette-only household exposure was associated with more asthma flares and activity-related symptoms.

Latine and Spanish-speaking patients had the largest increases in pediatric no-show and cancellation rates after Operation Midway Blitz, a Chicago-area immigration enforcement operation.

In a multi-institutional cohort of 84 patients 21 years or younger with sporadic colorectal cancer, 67 presented with stage III or IV disease and 45.2% died of CRC.

The Autus Size-Adjustable Valve can be implanted at about 13 mm and balloon-expanded to 22 mm as children grow, with no deaths or strokes among 62 patients studied.

The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.

The FDA approved 40 mg and 50 mg twice-daily leniolisib (Joenja) for children ages 4 to 11 years weighing at least 27 kg with activated PI3Kδ syndrome.

If approved, the expanded indication would make roflumilast cream 0.05% the first once-daily, steroid-free topical PDE4 inhibitor approved specifically for this age group.

The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years.

Among children treated with navepegritide throughout the double-blind period, mean TFA decreased from 9.1° at baseline to 7.7° at Week 52 and 6.9° at Week 104, a mean absolute change of −2.2° over 2 years.

In a parallel regulatory action, the European Medicines Agency has also validated a marketing application for Tivicay covering the neonatal indication.

Cadrenal has announced that it plans to seek FDA Rare Pediatric Disease Designation for tecarfarin in children with Kawasaki disease and coronary aneurysms.

Baloxavir marboxil is a first-in-class cap-dependent endonuclease inhibitor that functions as a prodrug.

The approval is based on data from the phase 3 STRIDE-13 trial.

New Brain Communications data show doxecitine and doxribtimine reduce mortality risk by up to 94% in early-onset thymidine kinase 2 deficiency.